Alimera Sciences Inc

Alimera Sciences — Technical Presentation (May 2011)

31 slides from Alimera Sciences's technical presentation, May 3, 2011

  1. Slide 1: Fluocinolone Acetonide in Diabetic Macular Edema (FAME) Study: 36-Month Results

    Fluocinolone Acetonide in Diabetic Macular Edema (FAME(tm)) Study: 36-Month Results Andrew N. Antoszyk, MD

  2. Slide 2: Potential Conflicts of Interest

    Potential Conflicts of Interest Consultant - AlconConsultant - Alimera SciencesConsultant and Speaker - GenentechThe FAME Study is sponsored by Alimera Sciences, Inc.

  3. Slide 3: ILUVIEN Drug Delivery Insert

    Nonbioerodible cylindrical tube; 3.5 mm long, 0.37 mm in diameterInjected through a self sealing wound via 25-gauge proprietary inserter Two doses studied; 0.2 µg and 0.5 µg of fluocinolone acetonide (FAc) per day ILUVIEN(r) Drug Delivery Insert ILUVIEN(r) is a registered trademark of Alimera Scienc

  4. Slide 4: Consistent and Low Daily Dosing

    Consistent and Low Daily Dosing In Vitro Average Daily Wet Release Rates Human Aqueous Humor Levels1 ILUVIEN delivers a rapid and sustained therapeutic effect over 36 months 1Campochiaro P, et al. Ophthalmol. 2010;117:1393-1399. 2Data on file. Alimera Sciences. 0.2 µg/d FAc0.5 µg/d FAc 0 0 1 2 3 4 5

  5. Slide 5: Baseline Characteristics and Demographics

    Baseline Characteristics and Demographics Baseline Characteristics and Demographics

  6. Slide 6: Baseline Visual Acuity and Foveal Thickness

    Baseline Visual Acuity and Foveal Thickness Baseline Visual Acuity and Foveal Thickness

  7. Slide 7: Patient Disposition

    Patient Disposition Patient Disposition

  8. Slide 8: ILUVIEN 36-Month Efficacy Results

    ILUVIEN 36-Month Efficacy Results

  9. Slide 9: Percentage of Patients With 15-Letter Improvement Over Baseline

    (CHART) (CHART) Months Patients (%) 27.8% 28.7% 18.9% P = .018 Percentage of Patients With ^ 15-Letter Improvement Over Baseline, FAME A + B Primary Readout 28.6% 28.7% 16.2% P = .002

  10. Slide 10: Mean Center Point Retinal Thickness Over Time

    (CHART) Mean Center Point Retinal Thickness Over Time, FAME A + B 280.0 µm 308.6 µm 299.9 µm Months Mean Center Point Thickness in Study Eye (µm) 0.5 µg/d FAc (n = 388) Control (n = 182) 0.2 µg/d FAc (n = 369) Difference in change from baseline vs controlP = .015 for 0.2 µg/d FAc P = .004 for 0.5 µg

  11. Slide 11: Study, Laser, and Off-Protocol Treatments

    Study, Laser, and Off-Protocol Treatments Control(n = 185) 0.2 µg/d FAc(n = 376) 0.5 µg/d FAc(n = 395) Study Treatments (Sham injection or FAc insert) Study Treatments (Sham injection or FAc insert) Study Treatments (Sham injection or FAc insert) Study Treatments (Sham injection or FAc insert) 1 tre

  12. Slide 12: Cataract-Related and IOP-Related Events

    Cataract-Related Events Cataract-Related Events a Phakic patients only.b For a minimum of 7 days. Patients, %(Study Eye) Control(n = 185) 0.2 µg/d FAc (n = 375) 0.5 µg/d FAc(n = 393) IOP > 30 mm Hg 4.3 18.4 22.9 Any IOP-lowering medsb 14.1 38.4 47.3 Trabeculoplasty 0.0 1.3 2.5 Incisional IOP-lowerin

  13. Slide 13: Subgroup Analysis Rationale

    Subgroup Analysis Rationale Pre-specified primary endpoint for FAME was met at month 24 readout, BUT:Did a subgroup of patients with DME have a greater benefit-to-risk ratio?Ideal subgroup must meet the following:Statistically significant VA results at months 24 and 36Greater benefit-to-risk ratioId

  14. Slide 14: Determination of DME Subgroup

    Determination of DME Subgroup At over 100 sites on 3 continents, investigators determined a date of diagnosis of DME at baseline as part of FAME study Best clinical judgment employed Time between date of diagnosis and date of randomization was "duration of DME at baseline"Across all patients randomi

  15. Slide 15: Baseline Demographics, DME ≥3 Years

    Baseline Demographics and Disease Characteristics, FAME A + B, DME ^ 3 Years FAME A + B, DME ^ 3 Years FAME A + B, DME ^ 3 Years Full Analysis Population

  16. Slide 16: Baseline Demographics, DME <3 Years

    Baseline Demographics and Disease Characteristics, FAME A + B, DME < 3 Years FAME A + B, DME < 3 Years FAME A + B, DME < 3 Years Full Analysis Population

  17. Slide 17: FAME A Duration of DME Subgroup Analysis

    FAME A Duration of DME Subgroup Analysis

  18. Slide 18: FAME A, DME ≥3 Years: 15-Letter Improvement

    (CHART) Months Patients (%) 31.8% 13.6% P = .010 Percentage of Patients With ^ 15-Letter Improvement Over Baseline, FAME A, DME ^ 3 Years Primary Readout P = .004 P < .001 Full Analysis Population

  19. Slide 19: FAME A, DME <3 Years: 15-Letter Improvement

    (CHART) Months Patients (%) 24.1% 28.6% P = .441 Percentage of Patients With ^ 15-Letter Improvement Over Baseline, FAME A, DME < 3 Years Primary Readout P = .836 P = .767 Full Analysis Population

  20. Slide 20: FAME B Duration of DME Subgroup Analysis

    FAME B Duration of DME Subgroup Analysis

  21. Slide 21: FAME B, DME ≥3 Years: 15-Letter Improvement

    (CHART) Months Patients (%) 36.4% 13.2% P = .004 Percentage of Patients With ^ 15-Letter Improvement Over Baseline, FAME B, DME ^ 3 Years Primary Readout P = .006 P < .001 Full Analysis Population

  22. Slide 22: FAME B, DME <3 Years: 15-Letter Improvement

    (CHART) Months Patients (%) 20.7% 27.0% P = .424 Percentage of Patients With ^ 15-Letter Improvement Over Baseline, FAME B, DME < 3 Years Primary Readout P = .886 P = .775 Full Analysis Population

  23. Slide 23: Combined Duration of DME Subgroup

    FAME A + B Duration of DME Subgroup

  24. Slide 24: Combined, DME ≥3 Years: 15-Letter Improvement

    (CHART) Months Patients (%) 34.0% 13.4% P < .001 Percentage of Patients With ^ 15-Letter Improvement Over Baseline, FAME A + B, DME ^ 3 Years Primary Readout P < .001 P < .001 Full Analysis Population

  25. Slide 25: Combined, DME <3 Years: 15-Letter Improvement

    (CHART) Months Patients (%) 22.3% 27.8% P = .275 Percentage of Patients With ^ 15-Letter Improvement Over Baseline, FAME A + B, DME < 3 Years Primary Readout P = .984 P = .958 Full Analysis Population

  26. Slide 26: 15-Letter Improvement by DME Duration

    Percentage of Patients With ^ 15-Letter Improvement Over Baseline, FAME A + B DME < 3 Years DME ^ 3 Years (CHART) Months Patients (%) 28.8% 34.0% 13.4% P < .001 P < .001 P = .002 P = .003 28.4% 34.4% 13.4% (CHART) Months 26.4% 22.3% 27.8% P = .275 P = .984 P = .793 P = .245 28.7% 21.7% 20.8% Full An

  27. Slide 27: Change in Excess Center Point Thickness and 15-Letter Response

    Mean Change in Excess Center Point Thickness Percentage of Patients With ^ 15-Letter Response DME < 3 Years DME ^ 3 Years (CHART) (CHART) (CHART) (CHART) FAME A + B, Full Analysis Population Months Patients (%) Months Patients (%) Months Change in Excess CPT (^m) Months Change in Excess CPT (^m) 0.2

  28. Slide 28: Cataract-Related and IOP-Related Events, DME ≥3 Years

    Cataract-Related Events Cataract-Related Events Patients, %(Study Eye) Control(n = 112) 0.2 µg/d FAc (n = 209) 0.5 µg/d FAc(n = 213) IOP > 30 mm Hg 5.4 14.8 21.1 Any IOP-lowering medsb 15.2 35.9 48.4 Trabeculoplasty 0.0 1.9 3.3 Incisional IOP-lowering surgery 0.0 5.3 8.9 IOP-Related Events FAME A +

  29. Slide 29: Cataract-Related and IOP-Related Events, DME <3 Years

    Cataract-Related Events Cataract-Related Events Patients, %(Study Eye) Control(n = 72) 0.2 µg/d FAc (n = 165) 0.5 µg/d FAc(n = 178) IOP > 30 mm Hg 2.8 23.0 24.7 Any IOP-lowering medsb 12.5 41.8 46.1 Trabeculoplasty 0.0 0.6 1.7 Incisional IOP-lowering surgery 1.4 4.2 7.3 IOP-Related Events FAME A + B

  30. Slide 30: Conclusions

    Conclusions Patients with DME ^ 3 years, treated with the 0.2 µg/day FAc insert:Had a greater rate of ^ 3-line gainers than the sham control patients at month 36 (34.0% vs 13.2%, P < .001)Required only 1 insert during the study in > 75% of casesHad an incidence of IOP-lowering surgery of 5.3%Visual

  31. Slide 31: Acknowledgments

    Acknowledgments The FAME Study Group956 Patients101 sites in North America, Europe and IndiaWisconsin Fundus Photograph Reading CenterBernie McCary - Endothelial Cell Count Reading CenterCROs: Chiltern, EMMES, SIRO, CovanceAlimera Sciences, Inc.pSivida, Inc.

Alimera Sciences — Technical Presentation (May 2011) on 6ix